• Cefepime (BMY-28142): Precision Modeling for Neuroinfection

  2026-08-04

  Explore how Cefepime (BMY-28142) advances central nervous system infection research and antimicrobial resistance modeling. This article provides a unique, protocol-driven perspective on optimizing blood-brain barrier penetration and neurotoxicity assessment using this broad-spectrum cephalosporin antibiotic.

• Mapping GCGR Small Molecule Binding: Insights from Dynamic C

  2026-08-04

  This study identifies and characterizes the binding sites of small-molecule antagonists on the human glucagon receptor (GCGR) using crystal structures and molecular dynamics simulations. By revealing the structural basis for antagonist selectivity and binding stability, the research advances rational drug design targeting GCGR for type 2 diabetes.

• Aclacinomycin A in rDNA Damage Modeling: Mechanistic Insight

  2026-08-03

  Explore how Aclacinomycin A, a dual topoisomerase inhibitor, enables advanced modeling of persistent rDNA damage and PML-nucleolar dynamics. This article offers a deeper mechanistic analysis, protocol guidance, and practical perspectives for cancer research.

• BAPTA and the Future of Calcium Signaling in Translational R

  2026-08-03

  This thought-leadership article explores the mechanistic and strategic value of BAPTA, a high-affinity calcium chelator, in enabling advanced studies of calcium signaling modulation and apoptosis within complex environmental exposure models. By integrating novel insights from recent research on nanoplastic and cadmium co-exposure and situating BAPTA within the evolving competitive and translational landscape, we offer actionable guidance for next-generation cell signaling studies.

• Primidone and Paraoxonase-1: Noncompetitive Inhibition by AE

  2026-08-02

  The reference study investigates the in vitro effects of common antiepileptic drugs, including Primidone (Mysoline), on human serum paraoxonase-1 (hPON1) activity. By quantifying inhibitory potency and mechanism, the work clarifies a potential link between antiepileptic therapy and altered antioxidant enzyme function, with implications for metabolic and vascular risk in epilepsy management.

• Novobiocin Blocks Membrane and Vacuole Formation in E. faeca

  2026-08-01

  The reference study demonstrates that novobiocin, an aminocoumarin antibiotic, inhibits both plasma membrane synthesis and vacuole formation in Enterococcus faecalis protoplasts by blocking DNA replication. These findings highlight a direct mechanistic link between bacterial DNA replication and membrane dynamics, informing the design of future antibacterial resistance and cell biology assays.

• Translatome Remodeling by Fasting: Fatty Acid Signaling and

  2026-07-31

  A recent Nature study uncovers how fasting remodels the liver translatome through phosphorylation of eIF4E, selectively promoting the translation of lipid catabolism and ketogenesis genes. This work reveals a novel fatty acid–AMPK–MNK–eIF4E signaling axis, linking dietary lipids to translational control and highlighting new targets for metabolic intervention and cancer therapy.

• Clodronate Liposomes: In Vivo Macrophage Depletion Workflows

  2026-07-31

  Clodronate Liposomes empower targeted, reproducible in vivo macrophage depletion for high-resolution immune modulation and mechanistic studies. This guide unpacks evidence-driven workflows, troubleshooting insights, and the translational value of this macrophage depletion reagent in immunotherapy resistance and complex disease models.

• GLP-1 (9-36) Amide: Advanced Antagonist Strategies in Metabo

  2026-07-30

  Explore the unique antagonist properties of GLP-1 (9-36) amide in the context of glucagon-like peptide-1 receptor signaling. This article delves into nuanced assay design, receptor cross-talk, and practical considerations, offering new insights for advanced metabolic and type 2 diabetes research.

• Senotherapeutic Peptides Reduce Biological Age in Human Skin

  2026-07-30

  This study identifies and validates a novel senotherapeutic peptide, Pep 14, capable of reducing cellular senescence and biological age in human skin models. The research demonstrates both mechanistic insight into senescence modulation and practical rejuvenation outcomes, informing future strategies in skin aging and senescence-targeted therapies.

• Applied Linoleic Acid (C18:2) Workflows for Oxidative Stress

  2026-07-29

  Linoleic Acid (C18:2(9Z,12Z)) enables reproducible modeling of redox balance, membrane fluidity, and nutritional deficiency across cell and erythrocyte assays. This article offers protocol enhancements, troubleshooting guidance, and bridges translational insights from recent lipid signaling research.

• γH2AX DNA Damage Detection Kit: Precision in DSB Assays

  2026-07-29

  The γH2AX DNA Damage Detection Kit (Mouse mAb/Red) empowers researchers to visualize and quantify DNA double-strand breaks with high sensitivity, streamlining workflows in DNA damage and repair research. Leveraging red immunofluorescence, this kit stands out in applications from genotoxicity assessment to advanced radiotherapy response studies.

• GPX3 Enhances Gemcitabine Sensitivity in Pancreatic Cancer

  2026-07-28

  This study reveals that GPX3 acts as a tumor suppressor in pancreatic cancer by inhibiting the JNK/c-Jun pathway, leading to reduced proliferation, migration, and invasion of cancer cells. Notably, GPX3 overexpression enhances the chemo-sensitivity of pancreatic cancer cells to gemcitabine, highlighting a promising avenue for overcoming drug resistance.

• TBK1 Inhibition Mitigates PDN by Targeting Microglial Pyropt

  2026-07-28

  This study uncovers a novel inflammatory mechanism in painful diabetic neuropathy (PDN) by demonstrating that TANK-binding kinase 1 (TBK1) activation in microglia triggers pyroptosis, leading to PDN. Targeting TBK1, either genetically or pharmacologically, significantly reduces neuropathic pain, offering new translational avenues for diabetes research and therapy.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Experimental Work

  2026-07-27

  Digoxin stands out as a potent Na+/K+ ATPase pump inhibitor, offering translational value in both cardiac and antiviral research workflows. This guide demystifies its protocol setup, cross-domain applications, and troubleshooting strategies, leveraging APExBIO’s high-purity Digoxin for reproducible results.

451 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page